Drug Trial Radar · NCT00361881
Efficacy and Safety Study of ME-609 and Acyclovir for Treatment of Herpes Simplex Labialis
Last checked: Nov 19, 2026Latest source record: Aug 18, 2008 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
1,443
Actual
Start
Jul 2006
Primary completion
Aug 2007
Study completion Dec 2007
Sponsor
- Lead sponsor
- MedivirIndustry
- Sponsor type
- Industry
- First posted
- Aug 9, 2006
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Double (participant, investigator)
- Primary purpose
- Prevention
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The purpose of this study is to determine whether ME-609 is more efficient than acyclovir and placebo for the treatment of recurrent herpes labialis.
Conditions
- Herpes Labialis
Interventions
ME-609Drug
Cream, dose 5 times daily during 5 days.
acyclovir in ME-609 vehicleDrug
Dose 5 times daily for 5 days
VehicleDrug
Dose 5 times daily for 5 days
Primary outcomes
What the sponsor says the trial is designed to measure.
- Proportion of subjects with non-ulcerative recurrences measured as the proportion of subjects in whom the study recurrence did not progress beyond the papule stage.Time frame: 5 days
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Coastal Caroline Research Center
Mt. Pleasant, South Carolina
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.